Association of Myocardial Injury With Serum Procalcitonin Levels in Patients With ST-Elevation Myocardial Infarction

Martin Reindl1, Christina Tiller1, Magdalena Holzknecht1

  • 1Cardiology and Angiology, University Clinic of Internal Medicine III, Medical University of Innsbruck, Innsbruck, Austria.

JAMA Network Open
|June 16, 2020
PubMed

Insights

Procalcitonin (PCT) levels did not correlate with myocardial damage in ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention. This suggests PCT is not a reliable marker for assessing cardiac injury in acute STEMI cases.

Area of Science:

  • Cardiology
  • Biomarkers
  • Inflammation

Background:

  • Acute ST-elevation myocardial infarction (STEMI) triggers inflammation, releasing biomarkers like CRP and white blood cells, complicating infection detection.
  • Procalcitonin (PCT) is a potential marker for bacterial infection, but its release in STEMI due to myocardial injury alone is not well understood.

Purpose of the Study:

  • To investigate serum PCT levels in acute STEMI patients post-primary percutaneous coronary intervention (PCI).
  • To determine associations between PCT and myocardial injury markers assessed by cardiac magnetic resonance (CMR) imaging.

Main Methods:

  • A prospective cohort study of 141 STEMI patients treated with primary PCI.
  • Serial measurements of PCT, hs-CRP, hs-cTnT, and white blood cell counts at 24 and 48 hours post-intervention.
  • Assessment of infarct size, microvascular obstruction, and intramyocardial hemorrhage using CMR.

Main Results:

  • PCT levels showed no significant correlation with infarct size or microvascular obstruction on CMR at 24 or 48 hours.
  • PCT levels were not significantly associated with intramyocardial hemorrhage at either time point.
  • In contrast, hs-CRP, hs-cTnT, and white blood cell counts correlated with CMR-determined myocardial damage.

Conclusions:

  • Circulating PCT levels are not associated with myocardial or microvascular damage in the acute phase after STEMI and primary PCI.
  • PCT is unlikely to be a useful biomarker for evaluating the extent of myocardial injury in STEMI patients.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
683
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
134
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
548
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
174
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
425
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
282